Journal: Cells

Article Title: Molecular Analysis of the Superior Efficacy of a Dual Epidermal Growth Factor Receptor (EGFR)-DNA-Targeting Combi-Molecule in Comparison with Its Putative Prodrugs 6-Mono-Alkylamino- and 6,6-Dialkylaminoquinazoline in a Human Osteosarcoma Xenograft Model

doi: 10.3390/cells12060914

Figure Lengend Snippet: Immunohistochemistry and Western blot analysis of the effects of ZR2002, JS84 and JS61 on tumor tissues. ZR2002 decreases the phosphorylation of EGFR (P-EGFR). ( A ) Representative sections of Saos-2 tumors stained for P-EGFR. ( B ) Western blots for P-EGFR (Tyr 1068) and EGFR, where β-actin was used as internal control. Each band corresponds to different tumor lysates. ( C ) Quantification of Western blot: ratio of band intensity between P-EGFR and EGFR total protein. Data are expressed as means ± SEM. * p < 0.05 between the two groups.

Article Snippet: The membranes were blocked with 5% BSA in PBS 1x with 0.1% Tween-20 and immunoblotted overnight with the following antibodies—P-EGFR (Tyr1068) (D7A5) (1:1000; #3777; Cell Signaling, Danvers, MA, USA), EGFR (1:1000; #2646; Cell Signaling, Danvers, MA, USA) and phospho-histone H2A.X (Ser139) (1:1000; #2577; Cell Signaling, Danvers, MA, USA)—for tumor-tissue-derived blots and immunoblotted with the EGFR antibody for tumor-cell-derived blots.

Techniques: Immunohistochemistry, Western Blot, Staining

Journal: iScience

Article Title: IGFBP3 induced by the TGF-β/EGFRvIII transactivation contributes to the malignant phenotype of glioblastoma

doi: 10.1016/j.isci.2023.106639

Figure Lengend Snippet:

Article Snippet: Rabbit mAb anti-p-EGFR (Tyr1068) (D7A5) , Cell Signaling Technology , Cat#3777; RRID: AB_2096270.

Techniques: Luciferase, Microarray, Recombinant, Lysis, Transfection, SYBR Green Assay, Enzyme-linked Immunosorbent Assay, Reporter Gene Assay, BIA-KA, Cell Cycle Assay, Sequencing, shRNA, Real-time Polymerase Chain Reaction, Plasmid Preparation, Software

Journal: Biomolecules & Therapeutics

Article Title: Picropodophyllotoxin Inhibits Cell Growth and Induces Apoptosis in Gefitinib-Resistant Non-Small Lung Cancer Cells by Dual-Targeting EGFR and MET

doi: 10.4062/biomolther.2022.113

Figure Lengend Snippet: Effects of PPT on EGFR or MET mediated signaling pathways. Cells were treated with PPT at the indicated concentration for 48 h, then protein expression levels were determined. HCC827GR cell lysates were subjected to western blotting to detect of p-EGFR (Tyr1068), EGFR, p-MET (Tyr1234/1235), MET, p-AKT (Ser473), AKT, p-ERK (Thr202/Tyr204) and ERK antibodies.

Article Snippet: Antibodies against p-EGFR (Tyr1068), EGFR, p-MET (Tyr1234/1235), MET, p-AKT (Ser473), AKT, p-ERK (Thr202/Tyr204), and ERK were purchased from Cell Signaling Biotechnology (Beverly, MA, USA).

Techniques: Concentration Assay, Expressing, Western Blot